Verastem Inc.

NASDAQ: VSTMHealthcare / Biotechnology / USA
1.38+0.0400+2.99%Vol 1 015 5091Y Perf -84.56%
Sep 16th, 2019 16:00
BID1.38 ASK1.40
Open1.34 Previous Close1.34
Pre-Market1.30 After-Trading1.38
 -0.04 -2.99%  - -%
Target Price
4.83 
Analyst Rating
Strong Buy 1.50
Potencial %
250.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/100 
Income Ranking
 —    -
Market Cap (mil)102 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
2.70 
Earnings Date
6th Nov 2019

Today's Price Range

1.311.40

52wk Range

1.169.32

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
6.15%
1 Month
7.81%
3 Months
-21.14%
6 Months
-55.63%
1 Year
-84.56%
3 Years
1.47%
5 Years
-85.24%
10 Years
-

Name / TickerPriceChg.Chg.%
VSTM1.380.04002.99
AAPL219.901.15000.53
GOOG1 231.30-8.2600-0.67
MSFT136.33-0.9900-0.72
XOM73.731.09001.50
WFC48.980.06000.12
JNJ129.54-1.2400-0.95
FB186.22-0.9700-0.52
GE9.380.04000.43
JPM119.16-1.0700-0.89
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.49-0.52-6.12
Q01 2019-0.46-0.51-10.87
Q04 2018-0.54-0.3731.48
Q03 2018-0.43-0.2932.56
Q02 2018-0.35-0.3014.29
Q01 2018-0.41-0.410.00
Q04 2017-0.38-0.43-13.16
Q03 2017-0.32-0.61-90.62
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.4210.64Positive
12/2019 QR-0.487.69Positive
12/2019 FY-2.04-3.55Negative
12/2020 FY-1.86-3.91Negative
Next Report Date6th Nov 2019
Estimated EPS Next Report-0.42
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1 015 509
Shares Outstanding (in ths.)74 141
Trades Count3 033
Dollar Volume1 382 248
Avg. Volume2 142 082
Avg. Weekly Volume862 405
Avg. Monthly Volume760 861
Avg. Quarterly Volume1 555 872
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.00

Verastem Inc.

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

CEO: Robert Forrester

Teplephone: +1 781 292-4200

Address: 117 Kendrick Street, Needham 02494, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News